Dantrium Intravenous and Insulin glargine and lixisenatide Subcutaneous
Determining the interaction of Dantrium Intravenous and Insulin glargine and lixisenatide Subcutaneous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: dantrolene
Brand name: Dantrium, Dantrium Intravenous, Revonto, Ryanodex
Synonyms: n.a.
Generic Name: insulin glargine / lixisenatide
Brand name: Soliqua 100/33
Synonyms: Insulin glargine and lixisenatide (Subcutaneous)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dantrium Intravenous-Insulin glargine, recombinant Subcutaneous
- Dantrium Intravenous-Insulin glulisine
- Dantrium Intravenous-Insulin Glulisine (Cartridges and Pens)
- Dantrium Intravenous-Insulin Glulisine (Vials)
- Dantrium Intravenous-Insulin glulisine Subcutaneous
- Dantrium Intravenous-Insulin human inhaled Inhalation
- Insulin glargine and lixisenatide Subcutaneous-Dantrolene
- Insulin glargine and lixisenatide Subcutaneous-Dantrolene Capsules
- Insulin glargine and lixisenatide Subcutaneous-Dantrolene Injection
- Insulin glargine and lixisenatide Subcutaneous-Dantrolene Intravenous
- Insulin glargine and lixisenatide Subcutaneous-Dantrolene Sodium
- Insulin glargine and lixisenatide Subcutaneous-Dapagliflozin